RxDoctor Payments Data

Robert Harrison, DC

Family · Las Cruces, NMNPI 1740253335

Payments from drug & device makers

$443in general payments, 2019–2025

Across 26 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$54
  • Novo Nordisk$51
  • Abbott$43
  • Novartis$41
  • GSK$39
  • AstraZeneca$37
  • plus $178 from 9 others

What the payments were for

  • Food & beverage$443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$443 in reported general payments places this provider in the 65th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$83,121
Medicare patients
254
Services billed
1,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$80,952
EliquisApixaban52$52,917
RybelsusSemaglutide33$48,570
JanuviaSitagliptin Phosphate28$40,823
TrulicityDulaglutide19$35,275
FarxigaDapagliflozin Propanediol22$29,131
MounjaroTirzepatide21$24,659
CreonLipase/Protease/Amylase13$23,732
Tresiba Flextouch U-200Insulin Degludec12$17,965
XareltoRivaroxaban19$17,382
LinzessLinaclotide26$14,259
SymbicortBudesonide/Formoterol Fumarate13$4,705
Levothyroxine Sodium347$4,017
Omeprazole166$3,105
Lisinopril347$3,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$51$129,522100 claims
Lilly USA, LLCTrulicity, Mounjaro$23$59,93440 claims
AbbVieCreon, Linzess$35$37,99139 claims
AstraZenecaFarxiga, Symbicort$37$33,83635 claims
Johnson & JohnsonXarelto$23$17,38219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,080 family providers in New Mexico.

Other family in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →